Search Results

Surgery for NETs Resources EDUCATIONAL WEBINARS "What Matters About Liver Surgery" with Dr. Hallet Watch here "Evolving Management of NET Liver Metastases" with Dr. Singh Watch here "Understanding Surgery for Liver NETs" with Dr. Clarke Watch here "Understanding Carcinoid Crisis" with Dr. Hallet Watch here "A Conversation with Three NET Surgeons" with Dr. Clarke, Dr. Gangi and Dr. Anaya Watch 'A Conversation with Three NET Surgeons' featuring Dr. Callisia Clarke, Dr. Alexandra Gangi and Dr. Daniel Anaya Saenz. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. Watch here "NET Surgery: Making Decisions & Preparing for Surgery" with Callisia Clarke, MD Is surgery the right treatment option for you? Dr. Callisia Clarke joined us for our annual patient conference to address surgery for NETs including decision-making & preparing for surgery. Watch here "Patient Story: How to Prepare for Surgery" NET patient Julie’s “show and tell” of tips, tricks, and specific items she found useful during her hospital stay and recovery at home. Click here for a list of the items Julie mentioned in this video. Watch here Click here for our full surgery video playlist. PODCAST EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW SURGERY FOR NETS To cut or not to cut? A crossroad many neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope answers the top 10 surgery questions for NETs. LISTEN NOW KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW ADDITIONAL SURGERY RESOURCES NET Quiz - Test Your Knowledge! How much do you really know about surgery and international radiology for NETs? Test your NET knowledge by taking this six question quiz based off of the NETWise podcast episode #3: “Surgery and Interventional Radiology for NETs.” Take the Quiz Blog Post - Practical Tips for Patients Preparing for Surgery Many NET patients undergo surgery as part of their treatment course. While their medical team might have specific preparation instructions, patients often wonder about practical concerns like how to plan, what to pack, and how to prepare the home... Read the Blogpost

<< Back Additional Resources WATCH "Understanding Alpha & the Evolving PRRT Landscape" with Dr. Udhayvir Singh Grewal Download Presentation Slides >>> "2024 Updates on Clinical Trials in Neuroendocrine Tumors" with Dr. Heloisa Soares - April 25, 2024 - LACNETS Patient Educational Event "Navigating Clinical Trials: Expectations vs Realities" with Taymeyah Al-Toubah, MPH - August 2023 LACNETS Patient Educational Event "The Latest in NET Clinical Trials" - 2023 LACNETS Patient Education Conference "Clinical Trials: Why, What & How" - 2023 LACNETS Patient Education Conference "Patient Story & Understanding Clinical Trial Terminology" - 2020 LACNETS Symposium "Update on NET Clinical Trials" with Dr. Heloisa Soares - March 2023 LACNETS Educational Event "How Clinical Practice Has Been Changed by Clinical Trials in the Last 10 Years" by Dr. Enrique Grande (Credit: INCA) In this 2022 recording for INCA, Dr. Enrique Grande, MD, PhD, MSc, gives a snapshot of NET research, how clinical trials inform clinical practice, and highlights key trials. "Practice Changing Research in NETS" by Prof. Jonathan R. Strosberg, President of NANETS (Credit: INCA) In this 2022 recording for INCA, Prof. Strosberg discusses the current NET clinical trials. "What is the Role of Patients in Trial Design and Efficacy" by Prof. Michael Michael (Credit: INCA) In this 2022 recording for INCA, Prof. Michael discusses the gaps in current NET research and the role of patients in clinical trials design. LISTEN Visit the podcast episode page for more resources >>> Visit the podcast episode page for more resources >>> READ "Why Participate in Clinical Trials?" Clinical Trials Glossary "How to Prepare for Clinical Trials" Info Sheet Glossary: Common Terms in Clinical Trials Navigating Clinical Trials: Expectations vs Realities - Slides from August 19, 2023 LACNETS Educational Event

Clinical Trials Guide Clinical Trials Guide LATEST ON CLINICAL TRIALS Browse by Trial: ACTION-1: Alpha PRRT with Ac-225 in GEP-NETs ALPHAMEDIX: Alpha PRRT with Pb-212 DOTAMTATE in NETs Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas Belzutifan-MK-6482 in PNET + PPGL + VHL CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors CDK4/6 Abemaciclib GEP-NETS CHM-2101 CAR-T cell for GI Cancers ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IL13Rα2 CAR T Cell Study for Solid Tumor Cancers LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib in NETs Lu-177 DOTATATE vs Everolimus in Lung NETs Lu-177 DOTATATE + M3814 (Peposertib) in GEP-NETs Lu-177 DOTATATE + Olaparib in GEP-NETs Lu-177 DOTATATE + Sunitinib in PNETs Lu-177 DOTATATE + Triapine in GEP-NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) NET RETREAT: Retreatment with 177Lu-DOTATATE vs Everolimus in Metastatic Midgut NET NETTER-P: Lutathera in Adolescent Patients (12-17) with GEP-NETs and PPGLs Olaparib + Usual Chemotherapy (Temozolomide) in PPGL Paltusotine in Carcinoid Syndrome SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029) Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) SWOG S2104: Adjuvant CAPTEM for High Risk pNET SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Chemotherapy for NEC (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC By type of disease or treatment Browse by trial Browse by Type of Disease or Treatment: Pancreatic NET (PNET) Click Here Lung/Bronchial NETs Click Here G3 Neuroendocrine Neoplasms (NEN) or High Grade Click Here Immunotherapy Click Here NIH/NCI Natural History Study for Neuroendocrine Neoplasms Click Here Additional Resources Click Here Gastrointestinal (GI) NETs Click Here Pheochromocytoma/ Paraganglioma Click Here Peptide Receptor Radionuclide Therapy (PRRT) Click Here Somatostatin Analogue (SSA) Click Here Other Click Here UNDERSTANDING CLINICAL TRIALS Finding and learning more about relevant neuroendocrine cancer clinical trials may feel overwhelming. While comprehensive databases are available to search for trials, it may be difficult to understand whether a trial is right for you. Our goal is to offer a resource with key, open clinical trials for those with neuroendocrine cancer (aka, neuroendocrine neoplasm or NEN, including neuroendocrine tumor or NET and neuroendocrine carcinoma or NEC). We hope this information will help you better understand clinical trials and empower you to discuss them with your medical team. You may browse the Clinical Trials Guide in the following ways: Browse by selecting a type of disease or treatment. For example, if you are interested in open trials for pancreatic neuroendocrine tumor (PNET), click on the “PNET” image below. If you are interested in exploring peptide receptor radionuclide therapy (PRRT) trials, click on the “PRRT” image below. Browse by the trial using the table of contents. Click on individual trials to learn more information. Use the Ancora.ai clinical trial finder by entering your location and specifics about your tumor to find appropriate clinical trials. Then, browse this clinical trial guide to learn more about the suggested trials. When exploring the Clinical Trials Guide, you will find a description of each trial and contact information. Many also include a video of a NET expert describing the trial. The videos explain the study and who is eligible to participate. You can consider clinical trials at any time during your NET journey. Options range from first-line treatments for those newly diagnosed to novel treatments for those who have already had multiple treatments. For more information on how your involvement may benefit you and the NET community, read Why Participate in Clinical Trials . Download "Glossary of Common Terms in Clinical Trials" >>> Download "Clinical Trials: How to Prepare" >>> Ancora Ancora.ai Ancora.ai is a neuroendocrine tumor clinical trial finder for patients and physicians developed by Ancora.ai and NorCalCarciNET. Ancora allows you to do a personalized search, filter and export results, and if interested, Ancora's patient team can help connect you to a trial site to begin the evaluation process. It's free and easy to use. Click here to access Ancora.ai >> DISCLAIMER: This information is for educational purposes only. The Neuroendocrine Cancer Foundation encourages you to discuss your individual care and treatment options with your medical team. The Neuroendocrine Cancer Foundation does not endorse any particular trial or treatment. This is not a complete list of available NET trials nor is it intended to be. For comprehensive information about available clinical trials, go to ClinicalTrials.Gov.

The Neuroendocrine Cancer Foundation serves the neuroendocrine cancer (or NET) community by connecting patients, caregivers, and medical professionals. Find educational resources and connect with other NET patients and caregivers. Clinical Trials Blog Resources by Topic Podcast UPCOMING EVENTS Oct 28, 2025 Register Nov 9, 2025 Register Visit our events page for more information >>> Make a Difference Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for neuroendocrine cancer patients and caregivers. Donate Sign up for email Stay up-to-date with neuroendocrine cancer news, educational information, monthly newsletters and ways to connect with other neuroendocrine cancer patients and caregivers. Make a Difference Donate today and help us provide support, and information on diagnosis, treatment options, research, and resources for NET patients and caregivers. DONATE ABOUT THE NEUROENDOCRINE CANCER FOUNDATION The Neuroendocrine Cancer Foundation provides a community of support and education for neuroendocrine tumor (or neuroendocrine cancer or NET) patients and caregivers. Learn Our educational programs, including webinars , patient education conferences , a video library , podcast , and blog , provide information on diagnosis, treatment options, research and resources. We develop patient-friendly educational content that brings the latest medical information and research studies to NET patients and caregivers. Advocate We advocate f or all people impacted by this rare disease to improve health outcomes through early diagnosis. We raise awareness about neuroendocrine and carcinoid cancers among healthcare professionals and the public. Connect Our inclusive global community includes NET patients, family members, and caregivers. The Neuroendocrine Cancer Foundation makes it possible for patients to share experiences, encouragement, and hope through support groups , Health Coaching , and NETCONNECT , a buddy program connecting a newly-diagnosed NET patient with a long-time patient. Seven Facts About NET Neuroendocrine cancer is also known as neuroendocrine tumor, or NET. NET is a rare cancer. In the United States, 7 in 100,000 people are diagnosed per year. NET can affect neuroendocrine cells throughout the body. NET is a difficult cancer to diagnose. Some (but not all) NET patients have symptoms from their cancer. The cause of NET is unknown. Seeking the opinion of a NET specialist is important for all NET patients. LATEST ON CLINICAL TRIALS Clinical Trials News Play Video Play Video 06:20 Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy Play Video Play Video 05:29 Dr. Jennifer Chan & Dr. Del Rivero Discuss Advancing NET Research at the 2025 INCA Summit In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami Play Video Play Video 03:51 Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment - Dr. Singh Explains The NETTER-2 phase 3 trial results show Lutathera® may be offered as first-line treatment for newly diagnosed grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). When compared to long-acting octreotide, Lutathera® reduced the risk of disease progression or death by 72% in patients with somatostatin receptors. “These positive results for Lutathera are practice-changing and offer new first-line treatment data for patients who have a significant unmet need. This study confirms the clinical benefit of first-line radioligand therapy (RLT) for newly diagnosed patients living with these types of advanced GEP-NETs. These findings should instill confidence among physicians in using Lutathera as a first-line treatment for patients with this life-threatening type of cancer.” — Dr. Simron Singh, NET expert, Sunnybrook Health Sciences Centre, Ontario, Canada. Read the full Novartis Press Release: https://www.novartis.com/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors Play Video Play Video 04:05 Dr. Soulen Talks About 2023 Highlights and His Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews Dr Michael Soulen, Interventional Radiologist at Penn. He talks about the highlights of 2023 and shares his hopes for 2024. Play Video Play Video 02:14 Dr. Kunz Shares 2023 Highlights and Her Hopes for 2024 Director of Programs and Outreach Lisa Yen interviews NANETS Past President, Dr. Pamela Kunz. She talks about the highlights of 2023 and shares her hopes for 2024. Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment >>> Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib >>> Clinical Trials Guide LATEST FROM NCF WATCH 400+ Videos on Various Topics 2024 NET Cancer Day Symposium LISTEN Hear Experts Answer Top 10 Questions on Each Topic "Against the Tide: The Mary Donlevy Story" TAKE ACTION Learn About Active Clinical Trials RECENT EDUCATIONAL EVENTS Play Video Play Video 01:27:39 Understanding Alpha & The Evolving PRRT Landscape • Dr. Grewal • 2025 NCF Event • September 22, 2025 The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. For more information, visit https://www.ncf.net/events/sep2025. Play Video Play Video 01:25:23 Nutrition & Diet Considerations for NETs • 2025 NCF Event • August 26, 2025 Nutrition can play a key role in living well with neuroendocrine cancer (neuroendocrine tumors or NETs). Join NET dietitian Meghan Laszlo for an informative session on nutrition and diet considerations for people living with neuroendocrine cancer. She will cover key topics including the use of pancreatic enzymes, managing hyperglycemia, navigating special diets, and understanding supplements. Whether you're newly diagnosed or further along in your journey, this webinar offers practical guidance to help you make informed nutrition choices that support your health and quality of life. For more information, visit ncf.net. Play Video Play Video 01:16:25 Living with NET: The Patient Perspective • 2025 NCF Event • July 10, 2025 Patients share their experiences on topics, including decision-making, coping strategies, lessons learned, challenges, and navigating relationships while living with neuroendocrine cancer. Hear about their personal journeys—filled with resilience, realities, and hope, that offer powerful insight into what it's like living with neuroendocrine cancer. Visit NCF.net/July2025 for more information. Play Video Play Video 01:33:27 "Evolving Management of Carcinoid Heart Disease" • Prashanth Venkatesh, MD, FACC • April 29, 2025 Learn from Cardiologist and Congenital Heart Disease Specialist, Dr. Prashanth Venkatesh from Cedars-Sinai Smidt Heart Institute in a virtual educational event on carcinoid heart disease. Dr. Venkatesh demystifies the topic and shares the latest developments in its diagnosis and treatment, including a novel minimally invasive approach to replace heart valves damaged by carcinoid heart disease. For more information and resources, visit NCF.net. Play Video Play Video 01:30:51 "Understanding Treatments for NETs and Rationale for Sequencing of Therapy" • Dr. Wolin • Apr 1, 25 Learn from internationally-renowned neuroendocrine cancer expert Dr. Edward Wolin in a discussion on the latest in neuroendocrine tumor treatments and understanding how to sequence them. Dr. Wolin has pioneered many of the NET treatments including somatostatin analogues (SSAs, sandostatin and octreotide), mTOR inhibitors (i.e. everolimus), anti-angiogenic drugs (i.e. cabozantinib), and peptide receptor radiotherapy (PRRT, i.e. Lutathera). Join us for an insightful presentation and live question and answer session. Learn more at https://www.ncf.net/events/apr2025 Play Video Play Video 01:49:57 "PRRT Nurse's Perspective: What to Expect with PRRT" • Linda Gardner, MSN, RN, VA-BC • Mar 7, 2025 Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. Learn more at https://www.ncf.net/events/mar2025 Play Video Play Video 01:28:12 "Deciphering Genetics & Genomics in Neuroendocrine Cancers" • Dr. Perez • Feb 7, 25 Learn the latest in genetics and genomics for neuroendocrine cancers from medical oncologist Dr. Kimberly Perez from Dana Farber Cancer Institute (DFCI) in Boston, Massachusetts. Dr. Perez has expertise in hereditary cancer syndromes and deciphers the topics of genetics and genomics. Learn more at LACNETS.org. Play Video Play Video 01:33:06 "Understanding GI NETs Found on Endoscopy: Gastric, Duodenal, Colon & Rectal" • Dr. Metz •Jan 28, 25 Learn from renowned Neuroendocrinologist Dr. David Metz, who discusses neuroendocrine tumors (NETs) found on endoscopy, including gastric, duodenal, colon and rectal NETs. Dr. Metz discusses which NETs can be found on endoscopies and how they are managed and treated. For more information, visit LACNETS.org. LATEST PODCAST EPISODES LISTEN LISTEN LISTEN LISTEN RESOURCES & INFORMATION FOR YOU Meetings Register for the upcoming educational webinars and programs Support Groups Learn about the NET patient and caregiver support groups Podcast A podcast series where neuroendocrine tumor (NET) experts answer the top 10 FAQs on various NET topics Resources Check our resource navigation guide which covers various topics from treatment options to wellness NETCONNECT Program A peer support system that connects newly-diagnosed patients with mentors Newly Diagnosed Newly-diagnosed NET patients can begin exploring here for resources and support NET VITALS A tool for patients and healthcare professionals to share vital information about a patient’s neuroendocrine cancer Clinical Trials Explore open clinical trials here Blog Read about various NET topics, inspiring survival stories, and tips to live fully and richly with cancer Patient & Caregiver Stories Find inspiration and hope from NET patient and caregiver stories Spanish Resources Explore Spanish-language resources for NET patients and caregivers Health Coaching Learn how you can receive one-on-one coaching sessions available to NET patients and caregivers I was officially diagnosed on June 29, 2022. I didn’t even know NETs existed. And today...less than a month later, I’ve learned so much thanks to the incredible resources that exist as a result of the beautiful NETs community. The resources available, especially the videos from the (Neuroendocrine Cancer Foundation) and the NET VITALS document, are so life-giving and helpful for the newly diagnosed. The Neuroendocrine Cancer Foundation contributes so much useful information to the NET community. — NET Patient

< Back to the upcoming events page ABOUT The field of PRRT (Peptide Receptor Radionuclide Therapy) is evolving rapidly, and patients are hearing more about new developments like alpha therapies, the recent NETTER-2 and COMPETE trial results, and other advances. Join medical oncologist Dr. Udhayvir Singh Grewal from the Winship Cancer Institute of Emory University as he breaks down what these changes mean for people living with neuroendocrine cancer. This webinar will help patients and caregivers make sense of emerging research and therapies—and what they may mean for the future of NET treatment. Download Presentation Slides >>> ABOUT DR. UDHAYVIR SINGH GREWAL Udhayvir Singh Grewal, MD Assistant Professor of Medical Oncology Winship Cancer Institute Emory University School of Medicine Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team. T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

Upcoming Events & Meetings Coping With Neuroendocrine Cancer: Managing Distress, Worry & Grief Oct 28, 2025 A neuroendocrine cancer diagnosis can bring emotional, mental, and psychological challenges that are just as difficult as the physical ones. Join licensed clinical psychologist Dr. Karen Kersting from the Medical College of Wisconsin for a supportive discussion on Coping with Neuroendocrine Cancer: Managing Distress, Worry & Grief. She will offer insights and practical strategies to help patients and caregivers navigate the full emotional and psychological impact of living with NETs. Register NCF Regional NET Patient Educational Event Nov 9, 2025 Join the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida, on Sunday, November 9th, from 8:30 am - 4:30 pm. Register The Latest on Immunotherapy for Neuroendocrine Cancer Dec 11, 2025 Immunotherapy is an exciting and rapidly advancing area in the treatment of neuroendocrine cancer. Join Dr. Aman Chauhan, medical oncologist at the University of Miami Sylvester Cancer Center, as he discusses the latest developments in immunotherapy for NETs. This webinar will cover current standard-of-care treatments as well as cutting-edge clinical trials involving DLL3-targeted therapies, oncolytic viruses, CAR T-cell therapy, and combination approaches. Whether you’re newly diagnosed or exploring new treatment options, this session will help you better understand the evolving landscape of immunotherapy in neuroendocrine cancer. Registration to Open Soon Virtual NET Patient & Caregiver Support Group (Weekly) Wednesday, Oct. 22, 29. Nov. 5, 12, 19, 26 2025 NOON - 1:30 PM Pacific Join NCF via ZOOM Weekly on Wednesdays from 12 - 1:30 PM Pacific Time. We provide a collective, empathetic space for information & experience sharing, support & community. For NET Patients & Caregivers Register Virtual NET Caregiver Support Group (Monthly on a Saturday) Next meeting Oct. 18, 8:00 - 10:00 AM Pacific We provide a space where NET caregivers can come together virtually for support and community. We encourage you to express your experiences, thoughts, and concerns amongst fellow caregivers. For NET caregivers only Register Click here for recent events

WEEKLY Virtual NET Support Group Meetings October 22, 2025 Wednesday, 12:00 - 1:30 PM Pacific Register We provide a welcoming space to come together virtually for knowledge sharing and community support. The focus of the meeting is to connect with others living with, or supporting someone living with, Neuroendocrine Tumor (NET). Both patients & caregivers discuss treatments, symptoms, living well and information uniquely related to this disease. This group is open to NET patients and caregivers. Join us via Zoom every Wednesday at 12 -1:30 PM Pacific Time. Before the live support meeting, please be sure to download Zoom on your preferred device: zoom.us/download Click here to watch a tutorial on how to download and join Zoom. *Please note all Zoom meeting details will be emailed to you within 24 hours of your registration. Questions? Email events@ncf.net . *Limited spots available. NET Support Group Registratin Register THANKS TO OUR SUPPORTERS

Our Team KAVYA VELAGAPUDI, MSW Executive Director and Board Member Kavya is the Executive Director and Board Member of the Neuroendocrine Cancer Foundation. Since 2015, Kavya has been involved with the organization providing fundraising and management support. She is a fundraising and management professional with 15 years of experience generating revenue and resources for various nonprofit organizations. With a Master's in Social Welfare and a concentration in Non-Profit Administration & Policy Advocacy, Kavya has a unique blend of development, management, and clinical skills. Before launching her independent fundraising consultancy Honu Fundraising, she was the Development Director of the International Museum of Women, now part of Global Fund for Women, in San Francisco. Before joining the Museum, Kavya was the Western Region Director of Starlight Children’s Foundation in Los Angeles overseeing all development, communications, and program services in Starlight’s Western Region. Contact: Kavya@NCF.net LISA YEN, NP, NBC-HWC Director of Programs & Outreach Lisa Yen was a nurse practitioner hospitalist for over 12 years prior to her husband’s diagnosis with advanced, metastatic pancreatic NET in January 2015. She brings a unique perspective to the Neuroendocrine Cancer Foundation as a medical professional and a caregiver. Once a regional support group, LACNETS has grown into a national NET patient advocacy group that now supports the Carcinoid Cancer Foundation, founded by Dr. Richard Warner. As the Director of Programs & Outreach, Lisa curates educational content for the Neuroendocrine Cancer Foundation’s virtual and in-person events, podcasts, annual conferences and symposiums, video resource library and Clinical Trials Guide. She facilitates patient and caregiver support groups and a support line. She has developed a peer mentorship program (NETCONNECT ), a health coaching program and wellness retreats . Lisa also co-created NET VITALS with LACNETS founder Giovanna Joyce Imbesi and City of Hope’s Dr. Daneng Li. In addition to developing content, Lisa attends national and international medical and scientific conferences to stay apprised of the latest in NET advances. She collaborates with NET experts, researchers, partners and patient advocates to improve access to education and care. Her passion is to help improve the quality of life for those affected by NET. Lisa was the recipient of the 2020 Monica Warner Award. She serves as treasurer on the executive board of INCA. She is a member of the NANETS NETPact Committee . Lisa earned a BA in psychology from Wheaton College in Illinois, a BSN from Loyola University of Chicago, and an MSN from UCLA’s School of Nursing’s Acute Care Nurse Practitioner Program. Through Vanderbilt, she became a Nationally Board-Certified Health and Wellness Coach (NBC-HWC) and is currently on the Vanderbilt and VA faculty, where she trains healthcare professionals and health coach trainees. When Lisa is not serving the NET community, she enjoys spending time with her husband, Tom, and their rescue dog, Skyler. She also enjoys traveling, snowboarding, and live theater. Watch Lisa and her husband Tom describe how they made decisions in this 2017 LACNETS video. Contact: Lisa@NCF.net HEATHER DAVIS Director of Community Engagement Heather Davis initially joined the Neuroendocrine Cancer Foundation as a NETCONNECT mentor for caregivers in 2019 after finding LACNETS to be an invaluable collective of medical resources, experts and caring support. Heather has nearly 20 years of account management experience in marketing. She has also served as her mother’s primary medical advocate since her pancreatic neuroendocrine cancer diagnosis in 2012. She earned her Bachelor’s Degree in Journalism/Advertising and Sociology from San Diego State University. As the Director of Community Engagement, she is eager to expand NET awareness and connect patients, caregivers and providers through this exceptional community. She is passionate that knowledge and collaboration make all the difference in both the quality of care and the quality of life for those affected by this rare disease. Heather enjoys learning and exploring new things with her nephews and having fun with family and friends. Contact: Heather@NCF.net BOARD OF DIRECTORS DONNA GAVIN Board President Donna Gavin is the sister of LACNETS founder Giovanna Joyce Imbesi and has been a board member of GeneratePossibility.org/LACNETS (now the Neuroendocrine Cancer Foundation) since 2009. Donna is dedicated to impactful work and has many years of experience in non-profit management and leadership. With a background in finance and law, she has served on boards and constituent groups of non-profit organizations for over 20 years. She is currently a senior grants administrator and paralegal at Cold Spring Harbor Laboratory on Long Island, New York, a scientific research institution and National Cancer Institute designated Cancer Center. Donna holds a BA from Williams College and a diploma in paralegal studies from New York University. MARY DONLEVY Board member Mary Donlevy joined the LACNETS Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS (now Neuroendocrine Cancer Foundation) since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time.

ALPHAMEDIX: Alpha PRRT with Pb-212 DOTAMTATE in NETs << Back ALPHAMEDIX - Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients CLINICALTRIALS.GOV IDENTIFIER: NCT05153772 DRUG/TREATMENT: AlphaMedix 212Pb-DOTAMTATE PHASE: 2 STATUS: Recruiting SPONSOR: Radiomedix, Inc. COLLABORATOR: Orano Med LLC Dr. Ebrahim Delpassand Discusses the AlphaMedix Trial (May 9, 2023) Dr. Heloisa Soares Discusses the AlphaMedix Trial (March 10, 2023) UPDATE October 8, 2025: Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors Sanofi reported that its experimental drug AlphaMedix™ (²¹²Pb-DOTAMTATE) met all its main goals in a phase 2 clinical trial, showing real benefits in people with certain gastro-pancreatic neuroendocrine tumors, whether or not they have had prior radiation treatment. The drug was generally well tolerated, and these results will inform future talks with regulators as Sanofi works toward potential approval. Read the full press release >>> DESCRIPTION: Radiomedix is sponsoring a multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive). In this open-label, multicenter, single-arm Phase 2 study, adult subjects with histologically confirmed NETs and positive somatostatin analog imaging, with no prior PRRT (PRRT naive) will be enrolled to receive 212Pb-DOTAMTATE. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Susan Cork EMAIL: scork@exceldiagnostics.com PHONE: 713-341-3203

< Back to the upcoming events page REGISTER Join the Neuroendocrine Cancer Foundation and the Sylvester Comprehensive Cancer Center, part of UHealth – University of Miami Health System, in Miami, Florida on Sunday, November 9th from 8:30 am - 4:30 pm. ABOUT Hear presentations from local NET experts and stories from those in the neuroendocrine cancer community. Learn about the latest in surgery, medical treatments, PRRT, symptom management, and clinical trials. Ask questions during the live question and answer sessions. Find out how you can spread awareness about neuroendocrine cancer. Post-Event Reception. There is no cost to attend. This event is made possible by the generosity of donors and sponsors. This event will not be broadcast. LOCATION The Newman Alumni Center University of Miami 6200 San Amaro Dr., Coral Gables, FL 33146 There will be a designated parking lot for this event and parking is being covered by NCF. AGENDA *Subject to change. Please check back closer to the event for the most accurate agenda. Time Topic Speaker 8:30 - 9 AM Registration & Breakfast 9 - 9:10 AM Welcome Neuroendocrine Cancer Foundation Team & Dr. Aman Chauhan 9:10 - 9:25 AM Demystifying Clinical Trials Taymeyah Al-Toubah 9:25 - 9:40 AM Role of Surgery in NETs Dr. Jashodeep Datta 9:40 - 9:50 AM Liver-Directed Therapy Dr. Lindsay Thornton 9:50 - 10:10 AM Q&A Faculty; Moderated by Dr. Aman Chauhan 10:10 - 10:30 AM Break 10:30 - 10:45 AM Systemic Therapies for NETs Dr. Jason Starr 10:45 - 11 AM PRRT for NETs Dr. Boris Naraev 11 - 11:15 AM The Latest in Managing Carcinoid Syndrome Dr. Lowell Anthony 11:15 - 11:30 AM Role of Advocacy in Advancing Care for Neuroendocrine Cancer Dr. Estelamari Rodriquez 11:30 - 11:45 AM How Do We Move the Needle in NETs: NCI's Perspective Dr. Elise Kohn 11:45 - 12:30 PM Q&A Faculty; Moderated by Dr. Aman Chauhan 12:30 - 1:30 PM Lunch 1:30 - 1:35 PM A NET Patient Journey Aramís Lorié 1:35 - 2:10 PM The Future of NETs: Emerging Therapies & Clinical Trials Dr. Aman Chauhan 2:10 - 2:30 PM Nutrition & Fitness in Cancer Tracy Crane, PhD, RDN 2:30 - 2:45 PM Documentary Trailer 2:45 - 3 PM Closing Neuroendocrine Cancer Foundation Team 3 - 4:30 PM Networking Reception TRAVEL GRANT NCF is offering a limited number of $250 travel grants for qualified attendees of this in-person event. To be considered for assistance, please fill out the short questionnaire below. Self-reported household income must fall within the 500% poverty guidelines. Check the chart below. Selected applicants must confirm their attendance at the registration table on November 9th to receive the funding. Household/Family Size Dollars Per Year 1 $75,300 2 $102,200 3 $129,100 4 $156,000 5 $182,900 6 $209,800 7 $236,700 8 $263,600 Click here to request a travel grant >>> The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

Learn more about the NET experts presenting on various topics during the 2024 LACNETS Neuroendocrine Tumor Patient Conference. 2025 Conference Speakers << Go back to the 2025 Annual Conference Page Overview of Neuroendocrine Cancer What is Neuroendocrine Cancer? Bhavana Konda, MD, MPH Medical Oncologist, Ohio State University Comprehensive Cancer Center (OSUCCC) Dr. Bhavana Konda is a Medical Oncologist with expertise in neuroendocrine tumors and endocrine-related cancers. She leads the Neuroendocrine Tumor and Endocrine Medical Oncology Section at the Ohio State University Comprehensive Cancer Center. Her research is dedicated to advancing treatment options to patients with these rare cancers through innovative clinical trials. Understanding Matters About Biomarkers & Blood Tests Thorvardur Halfdanarson, MD Medical Oncologist, Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson is President Emeritus of the North American Neuroendocrine Tumor Society (NANETS) as well. What Matters About Scans Nadine Mallak, MD Radiologist & Nuclear Medicine, Oregon Health & Science University Nadine Mallak, M.D. is a double boarded Associate Professor of Diagnostic Radiology at OHSU, in the divisions of Body Imaging, and Molecular Imaging & Therapy. She received her M.D. degree from Saint Joseph University Medical School in Beirut, Lebanon, followed by a Diagnostic Radiology residency at Hotel Dieu de France, Beirut. Subsequently, she finished fellowships in Neuroradiology and Abdominal Imaging, and a residency in Nuclear Medicine at the University of Iowa Hospitals and Clinics. Dr. Mallak is the clinical director of the PET/MRI program at OHSU. The scope of her clinical practice encompasses all aspects of molecular imaging and therapy, in addition to abdominal and pelvic imaging with modalities including ultrasound, CT, and MRI. Her research interests focus on molecular and hybrid imaging, particularly for prostate cancer, neuroendocrine tumors and pheochromocytoma/paraganglioma. In addition to her research projects, she’s passionate about education. She was voted by the radiology residents "outstanding teacher of the year" for the year 2019-2020, and by the graduating senior residents “outstanding board reviewer” for the year 2021-2022 In her free time, she enjoys painting, mostly with acrylic and watercolors, reading, hiking, and exploring the gorgeous nature in the Pacific Northwest. What Matters About Symptom Management Vineeth Sukrithan, MD Medical Oncologist, Ohio State University Comprehensive Cancer Center (OSUCCC) Dr. Vineeth Sukrithan is a medical oncologist who specializes in the study and treatment of neuroendocrine cancer, thyroid cancer and adrenocortical cancer. He utilizes traditional chemotherapy, molecularly targeted oral medications, novel immunotherapy and peptide-receptor radiotherapies in the treatment of these unique cancers. As a comprehensive cancer center, the OSUCCC – James has unrivaled experience and expertise in the treatment of neuroendocrine, thyroid and adrenal tumors. Their world-renowned faculty are leaders in the study and treatments of these rare cancers, and as such, they are able to provide their patients with options beyond standard therapies that may not be available anywhere else. The strong focus on translational research at The James means that the treatment breakthroughs of tomorrow are being discovered in their laboratories today. Dr. Sukrithan is part of a tight-knit team of surgical oncologists, radiation oncologists and interventional radiologists who work together to provide cutting-edge care for our patients with neuroendocrine tumors. In addition to his clinical work, Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC – James and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer. Dr. Sukrithan also serves as an assistant professor in the Division of Medical Oncology at The Ohio State University and has completed postdoctoral fellowships in clinical research at Johns Hopkins University. His research has been published in numerous peer-reviewed journals, including Cancer Research, American Journal of Clinical Oncology and Clinical Lung Cancer. As every individual’s cancer is molecularly unique in countless ways, Dr. Sukrithan believes in tailoring therapies to the individual with the precision made available through cutting-edge scientific research. He feels it is a privilege to make a difference in the lives of patients as we work together to achieve a cancer-free world. Surgery & Local Regional Therapies What Matters About Liver Surgery Julie Hallet, MD, MSc., FRCSC Surgical Oncologist, Sunnybrook Health Sciences Center Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. What Matters About Liver-Directed Therapy Alejandro Gabutti, MD Interventional Radiologist, National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ) University Hospital and National Reference Center for Liver Diseases Dr. Alejandro Gabutti, born in southern Mexico and moved to Mexico City for medical school. He received his medical degree from the UNAM (National University of Mexico) in 2008. After a year working as a general doctor in the mountain region of Chiapas, Mexico, he decided to continue his medical education as a Radiologist. By the year 2006 Alejandro was accepted in the INCMNSZ and completed a 4-year radiology program. Since the very beginning during his radiology training Alejandro showed a special interest in the interventional radiology procedures. He successfully completed a two-year interventional radiology fellowship at the INCMNSZ. At the conclusion of his fellowship, Alejandro was hired as part of the INCMNSZ radiology staff. In 2019 Dr. Gabutti moved to Milan Italy and completed a 1-year internship at the Istituto Nazionale dei Tumori, with special emphasis in oncological liver directed therapies. By his return to Mexico, Alejandro continues working as an Interventional Radiologist at the INCMSNZ, became the Interventional Radiology program professor (UNAM) and keeps working to improve liver malignancies imaging and treatments. Expert Panel: What Matters Most in Making Decisions About Surgery & Local Regional Therapies Daneng Li, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. Callisia Clarke, MD Surgical Oncologist, Medical College of Wisconsin Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Osman Ahmed, MD Interventional Radiologist, University of Chicago Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. William C. Chen, MD Radiation Oncologist, University of California San Francisco Dr. William C. Chen is a radiation oncologist and translational researcher. Dr. Chen received his undergraduate degree from Johns Hopkins University and completed medical school at the University of California, San Francisco. He completed his internal medicine preliminary internship at Kaiser San Francisco, followed by a residency in Radiation Oncology at UCSF. He is a Chan Zuckerburg Biohub Physician Scientist Fellow and a Helen Diller Family Cancer Center Physician Scientist Program in Clinical Oncology (PSPCO) Fellow. His research focuses on biomarker development, informatics, and clinical trial development with a focus on meningiomas and other malignancies of the central nervous system and beyond. Medical Management & Sequencing Treatments What Matters About Systemic Treatments Jennifer Chan, MD, MPH Medical Oncologist, Dana-Farber Cancer Institute Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. Dr. Chan focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. She is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. Dr. Chan has been principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and has been involved in studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors. She is a past chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS) and President of NANETS. Dr. Chan serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel. She is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute and the Board of Directors of NANETS. What Matters About PRRT: What is PRRT & How Does It Work? Cecilia Carreras Velázquez Nuclear Medicine, Hospital Ángeles Lomas Dr. Cecilia Carreras Velázquez is a board-certified specialist in Nuclear Medicine and Molecular Imaging, based in Mexico City. Graduated with honors from Centro Médico ABC (UNAM) in 2010 and completed a fellowship in Molecular Imaging in 2011. From 2012 to 2024, she served as Head of the Nuclear Medicine and PET/CT Department at Hospital Angeles Lomas, where she led the integration of advanced technology and the expansion of radionuclide-based diagnostic and therapeutic services. Pioneer in Mexico in implementing Lutetium-177 therapy for patients with Neuroendocrine Tumors and metastatic prostate cancer. In June 2024, Dr. Carreras assumed the position of Medical Director of Nuclear Medicine at the National Center for Radiology and Imaging within the Angeles Health System Hospitals in Mexico. Dr. Carreras has international experience, having collaborated with the research team at PET-Zentrum of Zentralklinik Bad Berka in Germany, focused on radionuclide therapies for neuroendocrine tumors. Since 2020, she has been a member of the Patient Safety and Quality Committee at Hospital Angeles Lomas, and in 2022, she was appointed Mexico Ambassador for the Oncidium Foundation, advocating for innovations in cancer treatment through nuclear medicine. For over a decade, she has actively participated in educational initiatives, specialty dissemination efforts, and patient-focused forums to enhance understanding and access to nuclear medicine advancements. What Matters About PRRT: Preventing and Managing Toxicities & Latest Advances Aman Chauhan, MD Medical Oncologist, University of Miami Health System Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. What Matters About Clinical Trials Pamela Kunz, MD Medical Oncologist, Yale Medicine Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including past President of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. Dr. Kunz was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021. Dr. Kunz was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity and received the 2024 'Distinguished Mentor Award' by the North American Neuroendocrine Tumor Society. X @PamelaKunzMD Expert Panel: What Matters Most in Making Decisions About Systemic Therapies & Sequencing Treatments J. Randolph Hecht, MD Medical Oncologist, UCLA Health Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. Alexandra Gangi, MD Division Director of Surgical Oncology, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the Division Director of Surgical Oncology and Director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. Erik Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training at Stony Brook University and subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty at Stanford for many years before moving to Oregon Health & Science University in 2018. Dr. Mittra is involved in all aspects of Nuclear Medicine but theranostics for oncology is of particular interest. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is a prior Medical Director of the Healing NET Foundation (HNF). David B. Zhen, MD Medical Oncologist, Fred Hutch Cancer Center Dr. David Zhen is a medical oncologist who specializes in treating patients with gastrointestinal cancers. His research centers around the development of clinical trials evaluating new therapies and combination approaches for the treatment of patients with gastrointestinal cancers, particularly pancreatic and gastroesophageal cancers. He is also conducting research to understand the interactions of the immune system in gastrointestinal cancers and how this can be manipulated to improve upon the response to immunotherapy drugs called checkpoint inhibitors, which block a braking system that cancers use to tamp down the immune response. Moderators: MARY DONLEVY NCF Board member and NET Patient Advocate Mary Donlevy joined the NCF Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time. Andrew Hendifar, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. << Go back to the 2025 Annual Conference Page

Learn more about the NET experts presenting on various topics during the 2024 LACNETS Neuroendocrine Tumor Patient Conference. 2024 LACNETS Conference Speakers Understanding NET Diagnosis: The Work-Up & What You Need to Know About Your NETs Chandrikha Chandrasekharan, MBBS Medical Oncologist, University of Iowa Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor at University of Iowa. She did her initial medical training in India at Kilpauk Medical College. She moved to the USA to complete her internal medicine residency at University of Florida College of Medicine at Jacksonville. Dr. Chandrasekharan is board certified in Medical Oncology and Palliative Medicine. After completing medical oncology fellowship at LSU Shreveport, she pursued an additional year of advanced oncology training in gastrointestinal malignancies at Mayo Clinic. Dr. Chandrasekharan's clinical practice and research interests include all gastrointestinal malignancies with a focus on neuroendocrine tumors. Understanding NET Scans Nadine Mallak, MD Radiologist & Nuclear Medicine, Oregon Health & Science University Nadine Mallak, M.D. is a double boarded Associate Professor of Diagnostic Radiology at OHSU, in the divisions of Body Imaging, and Molecular Imaging & Therapy. She received her M.D. degree from Saint Joseph University Medical School in Beirut, Lebanon, followed by a Diagnostic Radiology residency at Hotel Dieu de France, Beirut. Subsequently, she finished fellowships in Neuroradiology and Abdominal Imaging, and a residency in Nuclear Medicine at the University of Iowa Hospitals and Clinics. Dr. Mallak is the clinical director of the PET/MRI program at OHSU. The scope of her clinical practice encompasses all aspects of molecular imaging and therapy, in addition to abdominal and pelvic imaging with modalities including ultrasound, CT, and MRI. Her research interests focus on molecular and hybrid imaging, particularly for prostate cancer, neuroendocrine tumors and pheochromocytoma/paraganglioma. In addition to her research projects, she’s passionate about education. She was voted by the radiology residents "outstanding teacher of the year" for the year 2019-2020, and by the graduating senior residents “outstanding board reviewer” for the year 2021-2022 In her free time, she enjoys painting, mostly with acrylic and watercolors, reading, hiking, and exploring the gorgeous nature in the Pacific Northwest. Understanding Surgery for Liver NETs Callisia Clarke, MD Surgical Oncologist, Medical College of Wisconsin Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Understanding Carcinoid Crisis Julie Hallet, MD, MSc., FRCSC Surgical Oncologist, Sunnybrook Health Sciences Center Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. Understanding Liver-Directed Therapy Michael Soulen, MD FSIR FCIRSE Interventional Radiologist, University of Pennsylvania Michael C. Soulen, MD FSIR FCIRSE is the Professor of Radiology and Director of Interventional Oncology at the University of Pennsylvania Abramson Cancer Center and Director of Clinical Research in the Division of Interventional Radiology. His major clinical and research focus for the past 30 years has been image-guided cancer therapy (interventional oncology), with a specific focus on embolotherapy and ablative therapy of solid tumors in the liver and kidney. Animal research includes swine, rabbit, and rat models for liver-directed therapies, investigating novel embolic agents, novel ablation devices, and ultrasound-mediated drug delivery using novel drug-loaded microbubble contrast agents. Clinic trials focus on embolotherapies for primary liver cancers, liver metastases from colorectal and neuroendocrine tumors, and renal cell carcinomas. Current clinical investigations focus on synergy between locoregional and systemic therapies, including 1) pharmacologic modulation of the metabolic stress response under conditions of embolic ischemia; 2) IR therapies as immunostimulants combined with immune checkpoint inhibition, 3) radioembolization with radiosensitizing drugs; 4) serial biopsy for tumor cell culture, rapid drug screening, sequencing and testing in PDX mice, with the goal of personalized precision medicine; and 5) the first international randomized trial comparing embolotherapy techniques for neuroendocrine tumor liver metastases. Dr. Soulen received Research Mentor awards from the University of Pennsylvania Department of Radiology and the North American Neuroendocrine Tumor Society and the Gold Medal from the Society of Interventional Radiology. Understanding PRRT Eric Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training at Stony Brook University and subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty at Stanford for many years before moving to Oregon Health & Science University in 2018. Dr. Mittra is involved in all aspects of Nuclear Medicine but theranostics for oncology is of particular interest. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is a prior Medical Director of the Healing NET Foundation (HNF). Understanding the Latest in Systemic Treatments & Considerations for Treatment Sequencing Thorvardur Halfdanarson, MD Medical Oncologist, Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson currently serves as President for the North American Neuroendocrine Tumor Society (NANETS). NET Tumor Board Panel: Understanding NET Liver Metastases Jaydira Del Rivero, MD Endocrinologist & Medical Oncologist, National Institute of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Eric Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training through the MSTP (joint MD/PhD) program at Stony Brook University in New York in 2005. His master’s degree was in Anatomical Sciences, and his PhD in Biomedical Engineering. He subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty in Radiology at Stanford for 8 years, until moving to OHSU in 2018. Dr. Mittra is interested in all aspects of Nuclear Medicine imaging, therapy, and research. This includes adult and pediatric general nuclear medicine imaging with gamma camera and SPECT, PET imaging for oncology, cardiac, and neurologic applications, as well as bone densitometry (DXA imaging). Targeted Radioisotope Therapies (TRT) are of particular interest; including various applications in oncology and he is a nationally-recognized expert in this area. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is the current Medical Director of the Healing NET Foundation (HNF). Osman Ahmed, MD Interventional Radiologist, University of Chicago Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. Gangandeep Singh, MD Surgical Oncologist, City of Hope Dr. Singh is an internationally recognized liver and pancreas surgeon. He is the Chief of Surgical Oncology program, Head of the Hepatobiliary & Pancreatic Surgery Program and the Director of the Neuroendocrine Tumor Program at City of Hope Comprehensive Cancer Center (Phoenix). Dr. Singh is a seasoned leader with more than 20 years of experience building and leading several surgical teams to world-wide recognition. Dr. Singh began his faculty academic career at the Keck School of Medicine at University of Southern California (USC) in Los Angeles. From there, he was appointed as the Director of the Liver and Pancreas Center at the John Wayne Cancer Institute, Santa Monica, CA, where he also served as Chair of the Cancer Committee, and Vice President for Fellowship Education. In 2010, City of Hope (Duarte) recruited Dr. Singh to spearhead the liver and pancreatic cancer program. He was appointed Professor of Clinical Surgery and as the new Chief of the Division of Surgical Oncology (2011-2019) and hoisted their program to national recognition. He has an extensive referral base that reflects peer recognition of his clinical acumen and surgical expertise and is listed in “America’s Top Surgeons”, “Best Doctors of America”, “Super Doctors” and “Top Doctors of America.” Prior to his tenure in the Unites States, he earned is his Medical Degree from the Mahatma Gandhi Institute of Medical Sciences, India, and then trained at some of the finest cancer centers across the globe. These institutions include Tata Memorial Hospital and Cancer Center (Bombay, India), René Descartes University (Paris, France), and the Royal Liverpool University Hospital (Great Britain- England). In the USA, these institutes include the Marion Bessin Liver Center at the Albert Einstein College of Medicine (New York), Maricopa Medical Center (Phoenix), and the University of Iowa Hospitals & Clinics (Iowa City). Dr. Singh is a board-certified surgeon, a Diplomate of the American Board of Surgery and a Fellow of the American College of Surgeons. He is a member of some of the top elite surgical societies and has served as invited speaker/chair at several national and international conferences. He was a panel member of the National Comprehensive Cancer Network (NCCN) for Hepatobiliary Cancers for the last 10 years, that lays down the guidelines for the standard of care for these cancers; providing direction to both patients and physicians across the USA and the rest of the world. Dr. Singh has a very thoughtful, effective, and yet forceful approach to beating cancer, in a systematic fashion working with an outstanding multi-disciplinary team. Dynamic and compassionate, he is a skilled and an accomplished surgeon. He has extensive experience in liver and pancreatic diseases and other gastrointestinal cancers. His work is very well published with numerous publications in prestigious journals. His publications encompass complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions following difficult pancreatic surgery for pancreatic cancer, and advanced robotic surgery. His work in robotic surgery has been presented on the national podium at the Society of Surgical Oncology (SSO), Americas Hepato-Pancreato-Biliary Association (AHPBA), Society of Laparoscopic & Robotic Surgeons (SLRS) and other national meetings. An innovator at heart, Dr. Singh is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborative endeavors with engineers from California Institute of Technology (Caltech) & Harvey Mudd College. He has several invention disclosures and patents. In addition to a large clinical practice, Dr. Singh is passionately advancing cutting-edge translational research. He collaborates with City of Hope’s molecular biologists, X-ray crystallographers, structural chemists, and super-resolution scientists. A leader who is passionate about empowering teams and individuals to achieve their full potential, Dr. Singh has been recognized with several awards and leadership positions. Understanding NET Guidelines Jaydira Del Rivero, MD Endocronologist & Medical Oncologist, National Institute of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Understanding the Latest NET Clinical Trials Pamela Kunz, MD Medical Oncologist, Yale Medicine Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including President Emeritus of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. She was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021, she was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity. MODERATORS ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. DANENG LI, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. MARY DONLEVY LACNETS Board member and NET Patient Advocate Mary Donlevy joined the LACNETS Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time. Beth DeBlase NET Patient Beth was diagnosed in 2016 with metastatic, midgut NET. In that time, she has made aesthetic oncology and integrative therapies her passion. Her mission is to help enhance the quality of life for fellow cancer patients and caregivers, including herself, her four children, and husband. << Go back to the 2024 Annual Conference Page